메뉴 건너뛰기




Volumn 48, Issue 9, 2009, Pages 561-574

Clinical pharmacokinetics and pharmacodynamics of etravirine

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATORVASTATIN; CAFFEINE; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DARUNAVIR PLUS RITONAVIR; DEXTROMETHORPHAN; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; ENFUVIRTIDE; ETRAVIRINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MIDAZOLAM; NEVIRAPINE; OMEPRAZOLE; PAROXETINE; RALTEGRAVIR; RANITIDINE; RIFABUTIN; SAQUINAVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

EID: 69849107159     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/10895940-000000000-00000     Document Type: Review
Times cited : (103)

References (50)
  • 1
    • 26444595584 scopus 로고    scopus 로고
    • TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments
    • Oct
    • Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005 Oct; 79 (20): 12773-82
    • (2005) J Virol , vol.79 , Issue.20 , pp. 12773-82
    • Vingerhoets, J.1    Azijn, H.2    Fransen, E.3    Al, E.4
  • 2
    • 9644291579 scopus 로고    scopus 로고
    • TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1
    • Dec
    • Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004 Dec; 48 (12): 4680-6
    • (2004) Antimicrob Agents Chemother , vol.48 , Issue.12 , pp. 4680-6
    • Andries, K.1    Azijn, H.2    Thielemans, T.3    Al, E.4
  • 3
    • 22244453307 scopus 로고    scopus 로고
    • Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers [abstract no. 82]
    • Apr 28-30; Quebec (QC)
    • Scholler M, Hoetelmans R, Beets G, et al. Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers [abstract no. 82]. 6th International Workshop of Clinical Pharmacology of HIV Therapy; 2005 Apr 28-30; Quebec (QC)
    • (2005) 6th International Workshop of Clinical Pharmacology of HIV Therapy
    • Scholler, M.1    Hoetelmans, R.2    Beets, G.3    Al, E.4
  • 4
  • 5
    • 67149110590 scopus 로고    scopus 로고
    • Pharmacokinetics of etravirine are not affected by sex, age, race, use of enfuvirtide or treatment duration in HIV-1 infected patients [abstract no. P34]
    • Apr 7-9; New Orleans (LA)
    • Kakuda TN, Scholler-Gyure M, Peeters M, et al. Pharmacokinetics of etravirine are not affected by sex, age, race, use of enfuvirtide or treatment duration in HIV-1 infected patients [abstract no. P34]. 9th International Workshop of Clinical Pharmacology of HIV Therapy; 2008 Apr 7-9; New Orleans (LA)
    • (2008) 9th International Workshop of Clinical Pharmacology of HIV Therapy
    • Kakuda, T.N.1    Scholler-Gyure, M.2    Peeters, M.3    Al, E.4
  • 6
    • 69849086986 scopus 로고    scopus 로고
    • Determination of the in vitro transport characteristics of TMC125, evaluation of the possible role of P-glycoprotein in TMC125 transport and assessment of possible inhibition of P-glycoprotein activity by TMC125: A study in Caco-2 monolayers
    • study no. TMC125-NC183 (FK4784). Beerse: Johnson & Johnson Pharmaceutical Research & Development Data on file
    • Annaert P. Determination of the in vitro transport characteristics of TMC125, evaluation of the possible role of P-glycoprotein in TMC125 transport and assessment of possible inhibition of P-glycoprotein activity by TMC125: a study in Caco-2 monolayers. Nonclinical pharmacokinetics report, study no. TMC125-NC183 (FK4784). Beerse: Johnson & Johnson Pharmaceutical Research & Development, 2004. (Data on file)
    • (2004) Nonclinical Pharmacokinetics Report
    • Annaert, P.1
  • 7
    • 54749118543 scopus 로고    scopus 로고
    • Effects of different meal compositions and fasted state on the oral bioavailability of etravirine
    • Scholler-Gyure M, Boffito M, Pozniak AL, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy 2008; 28 (10): 1215-22
    • (2008) Pharmacotherapy , vol.28 , Issue.10 , pp. 1215-22
    • Scholler-Gyure, M.1    Boffito, M.2    Pozniak, A.L.3    Al, E.4
  • 8
    • 51649083570 scopus 로고    scopus 로고
    • A pharmacokinetic study of etravirine (TMC125) coadministered with ranitidine and omeprazole in HIV-negative volunteers
    • Scholler-Gyure M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) coadministered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol 2008; 66 (4): 508-16
    • (2008) Br J Clin Pharmacol , vol.66 , Issue.4 , pp. 508-16
    • Scholler-Gyure, M.1    Kakuda, T.N.2    De Smedt, G.3    Al, E.4
  • 9
    • 69849097292 scopus 로고    scopus 로고
    • The plasma protein binding and blood distribution of TMC125inanimals and man
    • study no. TMC125-NC143 (FK5135). Beerse: Johnson & Johnson Pharmaceutical Research & Development, 2004. (Data on file)
    • Mamidi RNVS. The plasma protein binding and blood distribution of TMC125inanimals and man. Nonclinical pharmacokinetics report, study no. TMC125-NC143 (FK5135). Beerse: Johnson & Johnson Pharmaceutical Research & Development, 2004. (Data on file)
    • Nonclinical Pharmacokinetics Report
    • Rnvs, M.1
  • 10
    • 34547737755 scopus 로고    scopus 로고
    • Invivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers [abstract no. M1342]
    • Oct 28-Nov 2; San Antonio (TX)
    • Raoof A, Mannens G, Mamidi R, et al. Invivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers [abstract no. M1342]. American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 2006 Oct 28-Nov 2; San Antonio (TX)
    • (2006) American Association of Pharmaceutical Scientists Annual Meeting and Exposition
    • Raoof, A.1    Mannens, G.2    Mamidi, R.3    Al, E.4
  • 13
    • 33845968601 scopus 로고    scopus 로고
    • Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223 [abstract no. TUPE0061]
    • Aug 13-18; Toronto
    • Cohen C, Steinhart CR, Ward DJ, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223 [abstract no. TUPE0061]. 16th International AIDS Conference; 2006 Aug 13-18; Toronto
    • (2006) 16th International AIDS Conference
    • Cohen, C.1    Steinhart, C.R.2    Ward, D.J.3    Al, E.4
  • 14
    • 34147134958 scopus 로고    scopus 로고
    • Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysis
    • Mar 30
    • Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 2007 Mar 30; 21 (6): F1-10
    • (2007) AIDS , vol.21 , Issue.6
    • Nadler, J.P.1    Berger, D.S.2    Blick, G.3    Al, E.4
  • 15
    • 49949104484 scopus 로고    scopus 로고
    • Single and multiple dose pharmacokinetics of etravirine administered as two different formulations in HIV 1 infected patients
    • Kakuda TN, Scholler-Gyure M, Workman C, et al. Single and multiple dose pharmacokinetics of etravirine administered as two different formulations in HIV 1 infected patients. Antiviral Ther 2008; 13: 655-61
    • (2008) Antiviral Ther , vol.13 , pp. 655-61
    • Kakuda, T.N.1    Scholler-Gyure, M.2    Workman, C.3    Al, E.4
  • 16
    • 78649232766 scopus 로고    scopus 로고
    • Bioavailability of the 100mg etravirine tablet dispersed in water and of the 25mg pediatric tablet formulation [abstract no. MOPE 0184]
    • Aug 2-8; Mexico City
    • Scholler-GyureM, Kakuda TN, van Solingen-Ristea RM, et al. Bioavailability of the 100mg etravirine tablet dispersed in water and of the 25mg pediatric tablet formulation [abstract no. MOPE 0184]. XII International AIDS Conference; 2008 Aug 2-8; Mexico City
    • (2008) XII International AIDS Conference
    • Scholler-Gyure, M.1    Kakuda, T.N.2    Van Solingen-Ristea, R.M.3
  • 17
    • 44649109705 scopus 로고    scopus 로고
    • Etravirine (TMC125) has no effect on QT and corrected QT interval in HIV-negative volunteers
    • Jun
    • Peeters M, Janssen K, Kakuda TN, et al. Etravirine (TMC125) has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharma-cother 2008 Jun; 42 (6): 757-65
    • (2008) Ann Pharma-cother , vol.42 , Issue.6 , pp. 757-65
    • Peeters, M.1    Janssen, K.2    Kakuda, T.N.3    Al, E.4
  • 18
    • 61349103126 scopus 로고    scopus 로고
    • Multiple dose pharma-cokinetics of etravirine administered as two different formulations alone or in combination with tenofovir disoproxil fumarate in healthy volunteers
    • Mar
    • Kakuda TN, Scholler-Gyure M, De Smedt G, et al. Multiple dose pharma-cokinetics of etravirine administered as two different formulations alone or in combination with tenofovir disoproxil fumarate in healthy volunteers. HIV Med 2009 Mar; 10 (3): 173-81
    • (2009) HIV Med , vol.10 , Issue.3 , pp. 173-81
    • Kakuda, T.N.1    Scholler-Gyure, M.2    De Smedt, G.3    Al, E.4
  • 22
    • 0242382799 scopus 로고    scopus 로고
    • Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the 'Cooperstown 5+1 cocktail'
    • Nov
    • Chainuvati S, Nafziger AN, Leeder JS, et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the 'Cooperstown 5+1 cocktail'. Clin Pharmacol Ther 2003 Nov; 74 (5): 437-47
    • (2003) Clin Pharmacol Ther , vol.74 , Issue.5 , pp. 437-47
    • Chainuvati, S.1    Nafziger, A.N.2    Leeder, J.S.3    Al, E.4
  • 23
    • 57049148690 scopus 로고    scopus 로고
    • Minimal pharmacokinetic in-teraction between the HIV non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects
    • Dec
    • Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic in-teraction between the HIV non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Anti-microb Agents Chemother 2008 Dec; 52 (12): 4228-32
    • (2008) Anti-microb Agents Chemother , vol.52 , Issue.12 , pp. 4228-32
    • Anderson, M.S.1    Kakuda, T.N.2    Hanley, W.3    Al, E.4
  • 24
    • 55049100707 scopus 로고    scopus 로고
    • An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects [abstract no. P4. 3/02]
    • Oct 24-27; Madrid
    • Davis J, Scholler-Gyure M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects [abstract no. P4. 3/02]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid
    • (2007) 11th European AIDS Conference
    • Davis, J.1    Scholler-Gyure, M.2    Kakuda, T.N.3    Al, E.4
  • 26
    • 58149489322 scopus 로고    scopus 로고
    • Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine
    • Ramanathan S, West S, Kakuda TN, et al. Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine. Antiviral Ther 2008; 13 (8): 1011-7
    • (2008) Antiviral Ther , vol.13 , Issue.8 , pp. 1011-7
    • Ramanathan, S.1    West, S.2    Kakuda, T.N.3    Al, E.4
  • 27
    • 69849110110 scopus 로고    scopus 로고
    • No pharmacokinetic interac-tion between TMC125 (etravirine; TMC125) and paroxetine in HIV-negative volunteers [abstract no. P4. 3/01]
    • Oct 24-27; Madrid
    • Scholler-Gyure M, Kakuda TN, Bollen S, et al. No pharmacokinetic interac-tion between TMC125 (etravirine; TMC125) and paroxetine in HIV-negative volunteers [abstract no. P4. 3/01]. 11th European AIDS Conference; 2007 Oct 24-27; Madrid
    • (2007) 11th European AIDS Conference
    • Scholler-Gyure, M.1    Kakuda, T.N.2    Bollen, S.3    Al, E.4
  • 28
    • 66949111695 scopus 로고    scopus 로고
    • Pharmacokinetic inter-action between the non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and atorvastatin in HIV-negative volunteers [abstract no. WEPEA106]
    • Jul 22-25; Sydney
    • Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetic inter-action between the non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and atorvastatin in HIV-negative volunteers [abstract no. WEPEA106]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney
    • (2007) 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention
    • Scholler-Gyure, M.1    Kakuda, T.N.2    De Smedt, G.3    Al, E.4
  • 30
    • 0344453707 scopus 로고    scopus 로고
    • Drug interactions with TMC125, a potent next generation non-nocleoside reverse transcriptase inhibitor [abstract no. A-1827]
    • Sep 27-30; San Diego (CA)
    • Baede P, Piscitelli S, Graham N, et al. Drug interactions with TMC125, a potent next generation non-nocleoside reverse transcriptase inhibitor [abstract no. A-1827]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002 Sep 27-30; San Diego (CA)
    • (2002) 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Baede, P.1    Piscitelli, S.2    Graham, N.3    Al, E.4
  • 32
    • 0003667696 scopus 로고    scopus 로고
    • US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adult and Adolescents Accessed 2008 Sep 9
    • US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://aidsinfo. nih. gov/contentfiles/AdultandAdolescentGL. pdf [Accessed 2008 Sep 9]
    • Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents [Online]
  • 33
    • 24044517189 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of ataza-navir: Surveillance ofpharmacotherapyinthe clinic
    • Sep
    • Ray JE, Marriott D, Bloch MT, et al. Therapeutic drug monitoring of ataza-navir: surveillance ofpharmacotherapyinthe clinic. Br J Clin Pharmacol 2005 Sep; 60 (3): 291-9
    • (2005) Br J Clin Pharmacol , vol.60 , Issue.3 , pp. 291-9
    • Ray, J.E.1    Marriott, D.2    Bloch, M.T.3    Al, E.4
  • 34
    • 34548784342 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice
    • Oct
    • Cleijsen RM, van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother 2007 Oct; 60 (4): 897-900
    • (2007) J Antimicrob Chemother , vol.60 , Issue.4 , pp. 897-900
    • Cleijsen, R.M.1    Van De Ende, M.E.2    Kroon, F.P.3    Al, E.4
  • 35
    • 34250828550 scopus 로고    scopus 로고
    • Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: A review
    • Apr
    • Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. New Microbiol 2007 Apr; 30 (2): 79-88
    • (2007) New Microbiol , vol.30 , Issue.2 , pp. 79-88
    • Gianotti, N.1    Soria, A.2    Lazzarin, A.3
  • 36
    • 33745792782 scopus 로고    scopus 로고
    • Virological responses to atazanavir-ritonavir-based regimens: Resistance-substitutions score and pharmacokinetic parameters (Reyaphar study)
    • Pellegrin I, Breilh D, Ragnaud JM, et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir Ther 2006; 11 (4): 421-9
    • (2006) Antivir Ther , vol.11 , Issue.4 , pp. 421-9
    • Pellegrin, I.1    Breilh, D.2    Ragnaud, J.M.3    Al, E.4
  • 37
    • 46449138764 scopus 로고    scopus 로고
    • The genotypic inhibitory quotient: A pre-dictive factor ofatazanavir response in HIV-1-infected treatment-experienced patients
    • Jun 1
    • Solas C, Colson P, Ravaux I, et al. The genotypic inhibitory quotient: a pre-dictive factor ofatazanavir response in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr 2008 Jun 1; 48 (2): 177-80
    • (2008) J Acquir Immune Defic Syndr , vol.48 , Issue.2 , pp. 177-80
    • Solas, C.1    Colson, P.2    Ravaux, I.3    Al, E.4
  • 38
    • 67650727422 scopus 로고    scopus 로고
    • Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance
    • Aug
    • Molina JM, Ait-Khaled M, Rinaldi R, et al. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. J Antimicrob Chemother 2009 Aug; 64 (2): 398-410
    • (2009) J Antimicrob Chemother , vol.64 , Issue.2 , pp. 398-410
    • Molina, J.M.1    Ait-Khaled, M.2    Rinaldi, R.3    Al, E.4
  • 39
    • 33644645264 scopus 로고    scopus 로고
    • Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir
    • Mar
    • Shelton MJ, Wire MB, Lou Y, et al. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chemother 2006 Mar; 50 (3): 928-34
    • (2006) Antimicrob Agents Chemother , vol.50 , Issue.3 , pp. 928-34
    • Shelton, M.J.1    Wire, M.B.2    Lou, Y.3    Al, E.4
  • 42
    • 34347327010 scopus 로고    scopus 로고
    • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
    • Jul 7
    • Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370 (9581): 29-38
    • (2007) Lancet , vol.370 , Issue.9581 , pp. 29-38
    • Madruga, J.V.1    Cahn, P.2    Grinsztejn, B.3    Al, E.4
  • 43
    • 34347354196 scopus 로고    scopus 로고
    • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
    • Jul 7
    • Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007 Jul 7; 370 (9581): 39-48
    • (2007) Lancet , vol.370 , Issue.9581 , pp. 39-48
    • Lazzarin, A.1    Campbell, T.2    Clotet, B.3    Al, E.4
  • 44
    • 34547739376 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of TMC125 inHIV-infected patients with non-nucleoside reverse transcriptase inhibitor and protease inhibitor resistance: TMC125-C223 [abstract no. L-131]
    • Feb 25-28; Los Angeles (CA)
    • Kakuda TN, Scholler-Gyure M, Peeters M, et al. Pharmacokinetics and pharmacodynamics of TMC125 inHIV-infected patients with non-nucleoside reverse transcriptase inhibitor and protease inhibitor resistance: TMC125-C223 [abstract no. L-131]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
    • (2007) 14th Conference on Retroviruses and Opportunistic Infections
    • Kakuda, T.N.1    Scholler-Gyure, M.2    Peeters, M.3    Al, E.4
  • 45
    • 84988644949 scopus 로고    scopus 로고
    • Pharmacokinetics (PK) and pharma-codynamics (PD) of etravirine (ETR) in treatment-experienced HIV-1 infected patients: Pooled 48-week results of DUET-1 and DUET-2 [abstract no. H-4056]
    • Oct 25-28; Washington, DC
    • Kakuda TN, Peeters M, Corbett C, et al. Pharmacokinetics (PK) and pharma-codynamics (PD) of etravirine (ETR) in treatment-experienced HIV-1 infected patients: pooled 48-week results of DUET-1 and DUET-2 [abstract no. H-4056]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25-28; Washington, DC
    • (2008) 48th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Kakuda, T.N.1    Peeters, M.2    Corbett, C.3    Al, E.4
  • 46
    • 34547780413 scopus 로고    scopus 로고
    • Pharmacokinetics of dar-unavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers
    • Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of dar-unavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12 (5): 789-96
    • (2007) Antivir Ther , vol.12 , Issue.5 , pp. 789-96
    • Scholler-Gyure, M.1    Kakuda, T.N.2    Sekar, V.3    Al, E.4
  • 47
    • 43749121302 scopus 로고    scopus 로고
    • DUET-1: Week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of etra-virine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients [abstract no. 790]
    • Feb 3-6; Boston (MA)
    • Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: Week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of etra-virine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients [abstract no. 790]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
    • (2008) 15th Conference on Retroviruses and Opportunistic Infections
    • Haubrich, R.1    Cahn, P.2    Grinsztejn, B.3    Al, E.4
  • 48
    • 43749103048 scopus 로고    scopus 로고
    • DUET-2: Week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of etra-virine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients [abstract no. 791]
    • Feb 3-6; Boston (MA)
    • Johnson M, Campbell T, Clotet B, et al. DUET-2: Week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of etra-virine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients [abstract no. 791]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
    • (2008) 15th Conference on Retroviruses and Opportunistic Infections
    • Johnson, M.1    Campbell, T.2    Clotet, B.3    Al, E.4
  • 49
    • 55049118579 scopus 로고    scopus 로고
    • Pooled 48-week analysis of DUET-I and DUET-2: Durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients [abstract no. P167]
    • Apr 24-27; Montreal
    • Trottier B, Johnson M, Katlama C, et al. Pooled 48-week analysis of DUET-I and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients [abstract no. P167]. 17th Annual Canadian Conference on HIV/AIDS Research; 2008 Apr 24-27; Montreal
    • (2008) 17th Annual Canadian Conference on HIV/AIDS Research
    • Trottier, B.1    Johnson, M.2    Katlama, C.3    Al, E.4
  • 50
    • 63849280451 scopus 로고    scopus 로고
    • 48-week pooled analysis of DUET-1 and DUET-2: The impact of baseline characteristics on virological response to etravirine (TMC125; ETR) [abstract]
    • Aug 2-8; Mexico City
    • Cahn P, Molina JM, Towner W, et al. 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virological response to etravirine (TMC125; ETR) [abstract]. XIIth International AIDS Conference; 2008 Aug 2-8; Mexico City
    • (2008) XIIth International AIDS Conference
    • Cahn, P.1    Molina, J.M.2    Towner, W.3    Al, E.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.